Atypical NMDA receptor expression in a diffuse astrocytoma, MYB- or MYBL1-altered as a trigger for autoimmune encephalitis

Marc Nikolaus1,2,3 · Arend Koch4 · Werner Stenzel4 · Sefer Elezkurtaj5 · Felix Sahm12 · Anna Tietze6 · Laura Stöffler7,13 · Jakob Kreye1,3,7,13 · Pablo Hernáiz Driever8 · Ulrich W. Thomale9 · Angela M. Kaindl1,2,10 · Markus Schuelke1,2,11 · Ellen Knierim1,2,11

Received: 31 March 2022 / Revised: 27 May 2022 / Accepted: 27 May 2022 / Published online: 21 June 2022
© The Author(s) 2022

Triggers of anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) include Herpes simplex encephalitis (HSE) [11] and ovarian teratomas [14]. The latter occur in 50% of adult NMDARE patients and are distinct from ovarian teratomas not associated with encephalitis. They contain neuronal tissue more often and exhibit (ganglio)glioma-like features with dysmorphic neurons and atypical NMDAR expression [4, 7]. Ectopic NMDARs could, therefore, initiate or maintain the formation of anti-NR1 antibodies—a tumor response leading to autoimmune encephalitis. Interestingly, brain tumors have not been implicated as triggers of NMDARE [2], despite their prevalence and expression profile that includes NMDARs [12].

Here, we present data on atypical NMDAR expression in glioneuronal brain tumors, in which dysmorphic neurons might induce antibody formation leading to autoimmune encephalitis.

We followed an atypical refractory NMDARE in a 21-month-old girl for more than 2 years. After a 4-week history of gait disturbance, behavioral changes, and seizures, MRI showed a T2-hyperintensity in the cerebellar white matter, which was interpreted as inflammatory lesion (Fig. 1d). CSF analysis revealed pleocytosis, type 2 oligoclonal bands, and intrathecal antibody synthesis. Screening for anti-neuronal antibodies detected anti-NR1 IgG in CSF (1:1,000) and serum (> 1:10,000) confirming NMDARE (Fig. 1a–c). With intensive immunotherapy, the child’s condition initially improved but a protracted course developed with fluctuating antibody titers and relapses refractory to therapy (Fig. 1g). When subsequent imaging showed growth of the presumed inflammatory lesion, navigated needle biopsy of the now suspected cerebellar tumor was performed (Fig. 1e). Based on histomorphology and molecular profile, we detected a diffuse astrocytoma, MYB or MYBL1-altered with MYBL1:MMP16-fusion [15] (Fig. 1i–o). In contrast to the MYB/MYBL1-altered astrocytoma presented here, these tumors are usually not located in the cerebellum and do not contain dysmorphic neurons [5]. After a third recurrence, the patient underwent subtotal tumor resection (Fig. 1f). This resulted in a sharp decrease in anti-NR1 titer (1:3) and significant sustained clinical improvement (Fig. 1g, h, detailed case in Supplementary 1, online resources).

In contrast to this case and unlike adults, the clinical presentation of NMDARE in children is dominated by neurologic rather than psychiatric symptoms, associated tumors are less common, and complete recovery is more likely [14]. In most children, no triggers are found.

To investigate a possible association between NMDARE and brain tumors, we analyzed tumor samples from the index patient (methods in Supplementary 2, online resources). Immunohistochemistry revealed atypical NR1-specific NMDAR positivity in somata of dysmorphic neurons detectable in the tumor (Fig. 1p, q). Glial tumor areas were negative. In contrast to cortical, hippocampal, and cerebellar control tissue, no neuropil signal was seen (Fig. 1r). Immunostaining with patient CSF was consistent with anti-NR1 signal of commercial antibodies. This confirmed atypical NMDAR expression on the patient’s dysmorphic neurons and suggested that autoantibodies binding the tumor were also responsible for NMDARE (Fig. 1s). Atypical NMDAR expression was specific for neuronal tissue. When analyzing low-grade tumors with different glial and neuronal composition from patients without reported autoimmune encephalitis, e.g., pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, or ganglioglioma, atypical NMDAR expression was detected only on dysmorphic neurons in...
Fig. 1 Atypical NMDAR expression in dysmorphic neurons of diffuse astrocytoma, MYB/MYBL1-altered, detected in a patient with NMDAR encephalitis. Immunostaining with CSF shows typical anti-NMDAR neuropil signal (green, DAPI co-localization blue) in mouse hippocampus (a) and cerebellum (b), and binding to NR1-expressing HEK293T-cells (negative control below) (e). SO: Stratum oriens, SP: Stratum pyramidale, SR: Stratum radiatum, ML: molecular layer, Pl.: Purkinje cell layer, GCL: granular cell layer. Size bars: 100 µm (top a, b), 20 µm (bottom a, b; both e). MRI 1 month post-symptom onset (pso) shows white matter T2-hyperintensity in right cerebellar hemisphere with minimal contrast uptake (d). Navigated biopsy (inset) of the growing mass 16 months pso allows tumor diagnosis (e). Follow-up 6 months after subtotal resection shows decrease in residual mass (f). Arrows indicate tumor; asterisks indicate biopsy and resection sites. Patient’s CSF and serum anti-NR1 titers fluctuate during treatment with steroids, plasmapheresis (PLEX), and immunoadsorption (IA), and drop after surgery (g). Symptoms, progression and treatment response assessed by physical examination and modified Rankin Scale (mRS) are presented semiquantitatively (h). Histomorphologic characterization reveals moderately cell-rich isomorphic glial tumor with narrow, pale eosinophilic cytoplasm and fibrillary processes. Dysmorphic neurons are seen within glial tumor matrix (i). Dysmorphic neurons located within tumor tissue are labeled with antibodies against synaptophysin (j). Tissue shows diffuse matrix-related GFAP reaction (k). Gliial tumor cells with fibrillary processes are highlighted in MAP2 staining (l). There is little proliferative activity (Ki67-labeling index 3%) (m). On methylation analysis (EPIC), tumor is assigned to “low grade glioma, MYB/MYBL1” (classifier score v11b4 0.82 and v12.5 0.93). There is a flat CNV profile with no significant chromosomal loss or gain (n). RNA sequencing demonstrates MYBL1:MMPI6 fusion (o). Dysmorphic neurons (arrowheads) in patient’s tumor show NMDAR-positivity with atypical concentration in somata rather than in neuropil (p). Signal is NR1-specific (q). Hippocampus (left) and cerebellum of healthy controls show typical neuronal signal (r). Immunostaining of fresh-frozen patient tumor with patient CSF (green) and commercial anti-NR1 (red) overlaps (yellow) confirming atypical NMDAR expression (s). Size bars: 200 µm (p, q, s), 100 µm (r), 20 µm (insets). Immunostaining with tumors of different glial and neuronal composition from individuals without autoimmune encephalitis show no NR1 signal in pilocytic astrocytoma (PA) (t), weak neuropil staining without NMDAR-positive somata in dysembryoplastic neuroependymal tumor (DNT) (u), and neuropil staining with atypical NMDAR expression on somata of dysmorphic neurons (arrowheads) in ganglioglioma (GG) (v). Similar NR1 signal is seen in CNS tissue from patients with Herpes simplex encephalitis (HSE), where areas of inflammatory infiltration show reduced neuropil staining but neurons with NMDAR-positive somata (w). NMDARE without brain tumor or viral infection shows normal NMDAR pattern in hippocampus (x, top), cerebellum (bottom), and dentate nucleus (y). Size bar: 200 µm (insets 100 µm)

Dysmorphic neurons are seen within glial tumor matrix and in the aforementioned NMDARE-associated ovarian teratomas (Fig. 1v, Supplementary Fig. 3 and 4, online resources). Tumors without such neurons were negative (Fig. 1t, u). However, we found similar atypical NMDAR expression within inflamed CNS tissue of HSE patients. Areas of severe inflammatory infiltration showed reduced neuropil signal, whereas NMDAR was expressed in the somata of neurons (Fig. 1w). Tissue from NMDARE patients without brain tumor or infection showed normal neuropil staining (Fig. 1x, y), making an epiphenomenon unlikely. Rather, atypical NMDAR expression is either a response to anti-tumor immune reactions or property of the dysmorphic neuronal tissue that facilitates such an anti-NMDAR antibody-mediated response.

Based on this example, it cannot be clarified with certainty to what extent dysmorphic cells present in tumor tissue or local neurons, e.g., from deep cerebellar nuclei, altered by inflammatory processes may induce NMDARE. The latter usually do not show atypical NMDAR expression (Supplementary Fig. 5, online resources).

Most patients with diffuse MYB/MYBL1-altered astrocytoma had epileptic seizures since childhood [15] and symptoms such as movement disorders, behavioral or mnemonic changes occur with both encephalopathy and glioneuronal tumors [13, 14]. This symptom overlap complicates differentiation and may lead to overlooking encephalitis in individual cases. Conversely, not every MRI abnormality should be attributed to encephalitis, but should be carefully investigated even in patients with known NMDARE, as it may mask an underlying neoplasm.

Recently, two isolated cases of NMDARE and astrocytoma have been reported [1, 9]. Both studies speculated a link between tumor and encephalitis, but did not perform further analyses. While astrocytes do indeed express NMDARs, this is rarely the case in astrocytomas. Notably, RNA-seq data here show no expression of NR1 [3], the major target of autoantibodies in NMDARE [6]. Together with the high prevalence of common astrocytomas [10], it remains unclear whether these tumors are indeed associated with NMDARE or whether this is coincidence.

This study suggests a link between certain brain tumors and NMDARE. We show atypical NMDAR expression on dysmorphic neurons that may have prompted antibody formation and subsequent autoimmune encephalitis. Tumor resection led to a decrease in these antibodies and terminated a previously refractory encephalitis, supporting the association ex juvantibus. Thus, following findings on NMDARE in ovarian teratomas, we propose an etiologic concept in which, in addition to HSE, the immunogenic properties of dysmorphic neurons, whether outside or inside the brain, serve as triggers for NMDARE.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00401-022-02447-y.

Acknowledgements The authors thank Petra Matylewska for her excellent technical assistance and the consortium of the LOGGIC Registry and LOGGIC Core Biobank through which the molecular analyses were performed.

Author contributions MN contributed to the conception of the study, performed and analyzed immunologic studies with patient CSF on mouse brain tissue, analyzed histologic data, and wrote the first draft of the manuscript. AK, WS, and FS performed histologic examination and tumor characterization. AT performed the radiological evaluation. LS
and JK performed cell-based immunoassay. UT took care of the patient. AK, WS, PHD, AMK and MS critically read the manuscript and contributed to the design of the study. EK contributed to the conception of the study, took care of the patient, analyzed and interpreted the patient data as well as the immunofluorescence data, and was instrumental in writing the manuscript. All authors read and approved the final version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. M.N. and J.K. are participants in the BIH-Charité Clinician Scientist Program funded by Charité—Universitätsmedizin Berlin and the Berlin Institute of Health. The study was supported by the German Research Foundation (DFG, SFB1315, FOR3004 to AMK, and DFG Germany Excellence Strategy—EXC-2049-390688087 to MS) and the Berlin Institute of Health (BIH) and Charité—Universitätsmedizin Berlin. The German HIT-LOGGIC-Registry is supported by Deutsche Kinderkrebsstiftung (DKKS 2021.03).

Availability of data and materials Data are available on request.

Declarations

Conflict of interest We have no competing interests to declare.

Consent for publication Consent for publication of individual images/detals was obtained from patient’s caregivers. Ethical approval for the study was obtained from the IRB of Charité (EA2/121/17).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Beretta F, Aliprandi A, Leo CD, Salmaggi A (2019) A case of anti-N-methyl-d-aspartate receptor encephalitis associated with glioma of the pons. J Clin Neurol 15:125–127. https://doi.org/10.3988/jcn.2019.15.1.125
2. Bost C, Chanson E, Picard G, Meyronet D, Mayeur M-E, Ducray F et al (2018) Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. J Neurol 265:2190–2200. https://doi.org/10.1007/s00415-018-8970-0
3. Brocke KS, Stauffner C, Luksch H, Geiger KD, Stepulak A, Marzahn J et al (2010) Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 9:455–468. https://doi.org/10.4161/cbt.9.6.10898
4. Chefdieville A, Treilleux I, Mayeur M-E, Couillault C, Picard G, Bost C et al (2019) Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-d-aspartate receptor encephalitis. Acta Neuropathol Commun 7:38. https://doi.org/10.1186/s40478-019-0693-7
5. Chiang J, Harreld JH, Tinkle CL, Moreira DC, Li X, Acharaya S et al (2019) A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol 138:1091–1092. https://doi.org/10.1007/s00401-019-02081-1
6. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091–1098. https://doi.org/10.1016/S1474-4422(08)70224-2
7. Day GS, Laiq S, Tang-Wai DF, Munoz DG (2014) Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol 71:717–724. https://doi.org/10.1001/jamaneurol.2014.488
8. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R et al (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30:5866–5875. https://doi.org/10.1523/jneurosci.0167-10.2010
9. Lu J, Zhang J, Miao A, Yin J, Zhu D, Lin X et al (2019) Brain astrocytoma misdiagnosed as anti-NMDAR encephalitis: a case report. BMC Neurol 19:210. https://doi.org/10.1186/s12883-019-1436-x
10. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R et al (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18:i1–i50. https://doi.org/10.1093/neuonc/nov297
11. Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C et al (2012) N-methyl-d-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 72:902–911. https://doi.org/10.1002/ana.23689
12. Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8:30. https://doi.org/10.1186/s40478-020-00902-z
13. Tejada ARQ, Miranda-Lloret P, Ros ML, Ramirez EP, Pancucci G, Barber AR et al (2021) Gangliogliomas in the pediatric population. Child’s Nerv Syst 37:831–837. https://doi.org/10.1007/s12618-020-03397-7
14. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, McKean-Cowdin R et al (2016) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157–165. https://doi.org/10.1016/S1474-4422(12)70310-1
15. Wefers AK, Stichel D, Schrumpf D, Coras R, Pages M, Tausiède-Espariat A et al (2020) Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol 139:193–209. https://doi.org/10.1007/s00401-019-02078-w

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Marc Nikolaus1,2,3 · Arend Koch4 · Werner Stenzel4 · Sefer Elezkurtaj5 · Felix Sahm12 · Anna Tietze6 · Laura Stöffler7,13 · Jakob Kreye1,3,7,13 · Pablo Hernáiz Driever8 · Ulrich W. Thomale9 · Angela M. Kaindl1,2,10 · Markus Schuelke1,2,11 · Ellen Knierim1,2,11

Marc Nikolaus
marc.nikolaus@charite.de
Arend Koch
arend.koch@charite.de
Werner Stenzel
werner.stenzel@charite.de
Sefer Elezkurtaj
sefer.elezkurtaj@charite.de
Felix Sahm
felix.sahm@med.uni-heidelberg.de
Anna Tietze
anna.tietze@charite.de
Laura Stöffler
laura.stoeffler@charite.de
Jakob Kreye
jakob.kreye@charite.de
Pablo Hernáiz Driever
pablo.hernaiz@charite.de
Ulrich W. Thomale
ulrich-wilhelm.thomale@charite.de
Angela M. Kaindl
angela.kaindl@charite.de
Markus Schuelke
markus.schuelke@charite.de

1 Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
2 Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
3 Berlin Institute of Health (BIH), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
4 Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
5 Institute of Pathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
6 Institute of Neuroradiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
7 Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
8 Department of Pediatric Oncology/Hematology and German HIT-LOGGIC-Registry for Low-Grade Glioma in Children and Adolescents, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
9 Department of Pediatric Neurosurgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
10 Institute of Cell Biology and Neurobiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
11 NeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
12 Department of Neuropathology, Ruprecht-Karls-University Heidelberg, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany
13 German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany